Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ATP4AATP4BAXLBTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CHRM2CHRM3CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4FLT3HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3KCNH2KMT2AMAP2K1MAP2K2MEN1MLNRMPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PLK4PPARGRENS1PR1SLC6A2SLC6A3SLC6A4SMOTYK2atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Acepromazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A known ✓ | P08908 | 7/20 | 0.88 |
| ▸ | DRD2 known ✓ | P14416 | 6/20 | 0.88 |
| ▸ | SLC6A2 known ✓ | P23975 | 6/20 | 0.88 |
| ▸ | SLC6A4 known ✓ | P31645 | 6/20 | 0.88 |
| ▸ | ADRA1A known ✓ | P35348 | 6/20 | 0.88 |
| ▸ | KCNH2 known ✓ | Q12809 | 6/20 | 0.88 |
| ▸ | ADRA2A known ✓ | P08913 | 5/20 | 0.88 |
| ▸ | DRD1 known ✓ | P21728 | 5/20 | 0.88 |
| ▸ | CHRM2 known ✓ | P08172 | 5/20 | 0.88 |
| ▸ | SLC6A3 known ✓ | Q01959 | 5/20 | 0.88 |
| ▸ | MTOR known ✓ | P42345 | 4/20 | 0.70 |
| ▸ | MEN1 known ✓ | O00255 | 5/20 | 0.69 |
| ▸ | KMT2A known ✓ | Q03164 | 5/20 | 0.69 |
| ▸ | ADRA2B known ✓ | P18089 | 4/20 | 0.60 |
| ▸ | ADRA2C known ✓ | P18825 | 4/20 | 0.60 |
| ▸ | HTR2A known ✓ | P28223 | 4/20 | 0.60 |
| ▸ | HRH1 known ✓ | P35367 | 4/20 | 0.60 |
| ▸ | HTR2B known ✓ | P41595 | 4/20 | 0.60 |
| ▸ | CHRM3 known ✓ | P20309 | 3/20 | 0.60 |
| ▸ | HTR2C known ✓ | P28335 | 3/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acepromazine SCHEMBL30620438 | 1.00 | CYP2D6 (0.88) | CYP2D6CYP1A2HTR1ALMNADRD2 | |
| Acepromazine SCHEMBL21803694 | 1.00 | CYP2D6 (0.88) | CYP2D6CYP1A2HTR1ALMNADRD2 | |
| Acepromazine SCHEMBL204733 | 1.00 | CYP2D6 (0.88) | CYP2D6CYP1A2HTR1ALMNADRD2 | |
| Acepromazine SCHEMBL29876174 | 1.00 | CYP2D6 (0.88) | CYP2D6CYP1A2HTR1ALMNADRD2 | |
| Acepromazine SCHEMBL30616039 | 1.00 | CYP2D6 (0.88) | CYP2D6CYP1A2HTR1ALMNADRD2 | |
| Acepromazine SCHEMBL7253707 | 1.00 | CYP2D6 (0.88) | CYP2D6CYP1A2HTR1ALMNADRD2 | |
| Acepromazine SCHEMBL29441481 | 0.94 | CYP2D6 (1.00) | CYP2D6CYP1A2HTR1ALMNADRD2 | |
| Acepromazine SCHEMBL29582179 | 0.94 | CYP2D6 (1.00) | CYP2D6CYP1A2HTR1ALMNADRD2 | |
| Acepromazine SCHEMBL73018 | 0.94 | CYP2D6 (1.00) | CYP2D6CYP1A2HTR1ALMNADRD2 | |
| Acepromazine SCHEMBL28142113 | 0.94 | CYP2D6 (1.00) | CYP2D6CYP1A2HTR1ALMNADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1146 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200095627-A1 | MOLECULAR SENSORS AND USES THEREOF | NEW YORK UNIVERSITY | 2020-03-26 | — | — | US | claimed |
| US-20170112829-A1 | USE OF COMPOUNDS BINDING TO THE SIGMA RECEPTOR LIGANDS FOR THE TREATMENT OF NEUROPATHIC PAIN DEVELOPING AS A CONSEQUENCE OF CHEMOTHERAPY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2017-04-27 | — | — | US | claimed |
| US-20110052723-A1 | USE OF COMPOUNDS BINDING TO THE SIGMA RECEPTOR LIGANDS FOR THE TREATMENT OF NEUROPATHIC PAIN DEVELOPING AS A CONSEQUENCE OF CHEMOTHERAPY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-03-03 | — | — | US | claimed |
| WO-2010101649-A2 | SIGMA 1 RECEPTOR INHIBITION AS A NOVEL THERAPEUTICAL APPROACH AGAINST HEPATITIS C VIRUS INFECTION | GASTAMINZA PABLO (US) | 2010-09-10 | — | — | WO | claimed |
| EP-2090311-A1 | Use of compounds binding to the sigma receptor ligands for the treatment of neuropathic pain developing as a consequence of chemotherapy | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2009-08-19 | — | — | EP | claimed |
| US-20090042898-A1 | USE OF COMPOUNDS ACTIVE ON THE SIGMA RECEPTOR FOR THE TREATMENT OF MECANICAL ALLODYNIA | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2009-02-12 | — | — | US | claimed |
| EP-1829534-A1 | Use of compounds binding to the sigma receptor for the treatment of metabolic syndrome | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-09-05 | — | — | EP | claimed |
| EP-1787679-A1 | Use of compounds binding to the sigma receptor for the treatment of diabetes-associated pain | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-05-23 | — | — | EP | claimed |
| EP-0487674-B1 | INJECTABLE SLOW-RELEASE GALENICAL | APLICACIONES FARMACEUTICAS (MX) | 1995-01-25 | — | — | EP | claimed |
| US-4213981-A | ACEPROMAZINE AND MIDFLUR | AMERICAN HOME PRODUCTS CORPORATION (US) | 1980-07-22 | — | — | US | claimed |
| US-12559503-B2 | Anthelmintic aza-benzothiophene and aza-benzofuran compounds | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2026-02-24 | — | — | US | disclosed |
| US-20260027098-A1 | MALLEABLE CONTROLLED RELEASE LOCAL ANESTHETIC WITH HEMOSTATIC COMPOSITION | RILENTO PHARMA LLC (US) | 2026-01-29 | — | — | US | disclosed |
| US-12534713-B2 | Chimeric alkaline phosphatase-like proteins | AM-PHARMA B.V. (NL) | 2026-01-27 | — | — | US | disclosed |
| US-20250382312-A1 | BORON CONTAINING PYRAZOLE COMPOUNDS, COMPOSITIONS COMPRISING THEM, METHODS AND USES THEREOF | BORAH INC (US) | 2025-12-18 | — | — | US | disclosed |
| US-12433879-B2 | Malleable controlled release local anesthetic with hemostatic composition | RILENTO PHARMA, LLC (US) | 2025-10-07 | — | — | US | disclosed |
| US-4534349-A | Absorbable sutureless nerve repair device | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1985-08-13 | — | — | US | disclosed |
| EP-0134813-A1 | ABSORBABLE NERVE REPAIR DEVICE AND METHOD. | MINNESOTA MINING & MFG (US) | 1985-03-27 | — | — | EP | disclosed |
| WO-1984003035-A1 | ABSORBABLE NERVE REPAIR DEVICE AND METHOD | MINNESOTA MINING & MFG (US) | 1984-08-16 | — | — | WO | disclosed |
| US-4370136-A | COATING WITH A POLYCARBONATE RESIN | WIDMAN LAWRENCE E | 1983-01-25 | — | — | US | disclosed |
| US-4213981-A | ACEPROMAZINE AND MIDFLUR | AMERICAN HOME PRODUCTS CORPORATION (US) | 1980-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250382312-A1 | BORON CONTAINING PYRAZOLE COMPOUNDS, COMPOSITIONS COMPRISING THEM, METHODS AND USES THEREOF | JAK3, JAK1, JAK2 | HTR1A 4593/4885DRD2 4327/4885SLC6A2 4044/4885 |
| US-20090042898-A1 | USE OF COMPOUNDS ACTIVE ON THE SIGMA RECEPTOR FOR THE TREATMENT OF MECANICAL ALLODYNIA | OPRM1, OPRL1, OPRK1 | HTR1A 66/4885DRD2 240/4885SLC6A2 183/4885 |
| US-20260027098-A1 | MALLEABLE CONTROLLED RELEASE LOCAL ANESTHETIC WITH HEMOSTATIC COMPOSITION | TRHDE, BTD, F2 | HTR1A 185/4885DRD2 9/4885SLC6A2 1984/4885 |
| US-12534713-B2 | Chimeric alkaline phosphatase-like proteins | ALPP, PHKA1, PHKA2 | HTR1A 4387/4885DRD2 4867/4885SLC6A2 1729/4885 |
| US-12559503-B2 | Anthelmintic aza-benzothiophene and aza-benzofuran compounds | HDAC5, NR5A2, HRH4 | HTR1A 1645/4885DRD2 3151/4885SLC6A2 2219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.